IP Library › Granted Patent US 10,428,145
Granted Patent B2
US 10,428,145 · App. 15/278,425 · Granted Oct 1, 2019

PD-1 binding proteins and methods of use thereof

Inventors: Brydon Bennett (San Diego, CA); Philip Paul Chamberlain (San Diego, CA); Kandasamy Hariharan (San Diego, CA); Pilgrim Jackson (San Diego, CA); Marilyn Kehry (San Diego, CA); Roli Khattri (San Diego, CA); Monica Leung (San Diego, CA); Lisa Morrison (San Diego, CA); Jeonghoon Sun (San Diego, CA); Sanaa Torres (San Marcos, CA); Henry H. Chan (Poway, CA)
Assignee: Celgene Corporation
C07K16/2818A61K2039/505A61P35/00C07K2317/24C07K2317/33C07K2317/34C07K2317/55C07K2317/71C07K2317/732C07K2317/734C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,145
App. No.
15/278,425
Granted
Oct 1, 2019
Kind
B2
Abstract

Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

Claims (197)

1. An antibody or antigen-binding fragment thereof that binds to PD-1, wherein the antibody or antigen-binding fragment comprises:

a light chain variable region (VL) comprising:

a VL complementarity determining region 1 (CDR1) comprising SEQ ID NO:1,

a VL CDR2 comprising SEQ ID NO:2, and

a VL CDR3 comprising SEQ ID NO:3; and

a heavy chain variable region (VH) comprising:

a VH CDR1 comprising SEQ ID NO:4,

a VH CDR2 comprising SEQ ID NO:5, and

a VH CDR3 comprising SEQ ID NO:6.

2. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:8.

3. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:10.

4. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:11.

5. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:12.

6. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:13.

7. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:8; and

a VH comprising an amino acid sequence of SEQ ID NO:11.

8. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:8; and

a VH comprising an amino acid sequence of SEQ ID NO:12.

9. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:8; and

a VH comprising an amino acid sequence of SEQ ID NO:13.

10. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:10; and

a VH comprising an amino acid sequence of SEQ ID NO:11.

11. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:10; and

a VH comprising an amino acid sequence of SEQ ID NO:12.

12. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:10; and

a VH comprising an amino acid sequence of SEQ ID NO:13.

13. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

14. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

15. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

16. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

17. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

18. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

19. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

20. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

21. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

22. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

23. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

24. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

25. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

26. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

27. The antibody or antigen-binding fragment of 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

28. The antibody or antigen-binding fragment of 7 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

29. The antibody or antigen-binding fragment of 8 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

30. The antibody or antigen-binding fragment of 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

31. The antibody or antigen-binding fragment of 10 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

32. The antibody or antigen-binding fragment of 11 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

33. The antibody or antigen-binding fragment of 12 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

34. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

35. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

36. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

37. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

38. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

39. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

40. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

41. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

42. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

43. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

44. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

45. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

46. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

47. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

48. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

49. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

50. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

51. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

52. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

53. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

54. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

55. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

56. The antibody or antigen-binding fragment of claim 7 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

57. The antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

58. The antibody or antigen-binding fragment of claim 9 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

59. The antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

60. The antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

61. The antibody or antigen-binding fragment of claim 12 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

62. The antibody or antigen-binding fragment of claim 48 , wherein the antibody or antigen-binding fragment further comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

63. The antibody or antigen-binding fragment of claim 49 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

64. The antibody or antigen-binding fragment of claim 50 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

65. The antibody or antigen-binding fragment of claim 51 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

66. The antibody or antigen-binding fragment of claim 52 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

67. The antibody or antigen-binding fragment of claim 53 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

68. The antibody or antigen-binding fragment of claim 54 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

69. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain comprising an amino acid sequence of SEQ ID NO:31.

70. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:32.

71. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:

a light chain comprising an amino acid sequence of SEQ ID NO:31; and

a heavy chain comprising an amino acid sequence of SEQ ID NO:32.

72. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:33.

73. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:

a light chain comprising an amino acid sequence of SEQ ID NO:31; and

a heavy chain comprising an amino acid sequence of SEQ ID NO:33.

74. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:34.

75. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:

a light chain comprising an amino acid sequence of SEQ ID NO:31; and

a heavy chain comprising an amino acid sequence of SEQ ID NO:34.

76. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:35.

77. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:

a light chain comprising an amino acid sequence of SEQ ID NO:31; and

a heavy chain comprising an amino acid sequence of SEQ ID NO:35.

78. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a monoclonal antibody.

79. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a humanized antibody.

80. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a human antibody.

81. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a chimeric antibody.

82. The antibody or antigen-binding fragment of claim 79 , wherein the humanized antibody is a deimmunized antibody.

83. The antibody or antigen-binding fragment of claim 79 , wherein the humanized antibody is a composite human antibody.

84. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment is a Fab, a Fab′, a F(ab′) 2 , a Fv, a scFv, a dsFv, a diabody, a triabody, a tetrabody, or a multispecific antibody formed from antibody fragments.

85. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment is conjugated to an agent.

86. The antibody or antigen-binding fragment of claim 85 , wherein the agent is selected from the group consisting of a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound, and a chemiluminescent compound.

87. An antibody or antigen-binding fragment thereof that binds to PD-1, wherein the antibody or antigen-binding fragment comprises:

a VL comprising:

a VL CDR1 comprising SEQ ID NO:7,

a VL CDR2 comprising SEQ ID NO:2, and

a VL CDR3 comprising SEQ ID NO:3; and

a VH comprising:

a VH CDR1 comprising SEQ ID NO:4,

a VH CDR2 comprising SEQ ID NO:5, and

a VH CDR3 comprising SEQ ID NO:6.

88. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:9.

89. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:11.

90. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:12.

91. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:13.

92. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:9; and

a VH comprising an amino acid sequence of SEQ ID NO:11.

93. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:9; and

a VH comprising an amino acid sequence of SEQ ID NO:12.

94. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises

a VL comprising an amino acid sequence of SEQ ID NO:9; and

a VH comprising an amino acid sequence of SEQ ID NO:13.

95. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

96. The antibody or antigen-binding fragment of claim 92 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

97. The antibody or antigen-binding fragment of claim 93 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

98. The antibody or antigen-binding fragment of claim 94 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

99. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

100. The antibody or antigen-binding fragment of claim 92 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

101. The antibody or antigen-binding fragment of claim 93 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

102. The antibody or antigen-binding fragment of claim 94 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

103. The antibody or antigen-binding fragment of 87, wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

104. The antibody or antigen-binding fragment of 92, wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

105. The antibody or antigen-binding fragment of 93, wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

106. The antibody or antigen-binding fragment of 94, wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

107. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

108. The antibody or antigen-binding fragment of claim 92 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

109. The antibody or antigen-binding fragment of claim 93 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

110. The antibody or antigen-binding fragment of claim 94 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

111. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

112. The antibody or antigen-binding fragment of claim 92 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

113. The antibody or antigen-binding fragment of claim 93 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

114. The antibody or antigen-binding fragment of claim 94 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

115. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

116. The antibody or antigen-binding fragment of claim 92 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

117. The antibody or antigen-binding fragment of claim 93 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

118. The antibody or antigen-binding fragment of claim 94 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

119. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

120. The antibody or antigen-binding fragment of claim 92 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

121. The antibody or antigen-binding fragment of claim 93 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

122. The antibody or antigen-binding fragment of claim 94 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

123. The antibody or antigen-binding fragment of claim 115 , wherein the antibody or antigen-binding fragment further comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

124. The antibody or antigen-binding fragment of claim 116 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

125. The antibody or antigen-binding fragment of claim 117 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

126. The antibody or antigen-binding fragment of claim 118 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

127. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:32.

128. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:33.

129. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:34.

130. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:35.

131. The antibody or antigen-binding fragment of claim 87 , wherein the antibody is a monoclonal antibody.

132. The antibody or antigen-binding fragment of claim 87 , wherein the antibody is a humanized antibody.

133. The antibody or antigen-binding fragment of claim 87 , wherein the antibody is a human antibody.

134. The antibody or antigen-binding fragment of claim 87 , wherein the antibody is a chimeric antibody.

135. The antibody or antigen-binding fragment of claim 132 , wherein the humanized antibody is a deimmunized antibody.

136. The antibody or antigen-binding fragment of claim 132 , wherein the humanized antibody is a composite human antibody.

137. The antibody or antigen-binding fragment of claim 87 wherein the antibody or antigen-binding fragment is a Fab, a Fab′, a F(ab′) 2 , a Fv, a scFv, a dsFv, a diabody, a triabody, a tetrabody, or a multispecific antibody formed from antibody fragments.

138. The antibody or antigen-binding fragment of claim 87 , wherein the antibody or antigen-binding fragment is conjugated to an agent.

139. The antibody or antigen-binding fragment of claim 138 , wherein the agent is selected from the group consisting of a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound, and a chemiluminescent compound.

140. A composition comprising the antibody or antigen-binding fragment of claim 1 , and a pharmaceutically acceptable carrier.

141. A polynucleotide comprising nucleotide sequences encoding a VH, a VL, or both a VH and a VL of the antibody of claim 1 .

142. The polynucleotide of claim 141 , wherein the polynucleotide is operably linked to a promoter.

143. A vector comprising the polynucleotide of claim 141 .

144. A cell comprising the polynucleotide of claim 141 .

145. A cell comprising the vector of claim 144 .

146. A cell producing the antibody or antigen-binding fragment of claim 1 .

147. A kit comprising the antibody or antigen-binding fragment of claim 1 .

148. A composition comprising the antibody or antigen-binding fragment of claim 87 , and a pharmaceutically acceptable carrier.

149. A polynucleotide comprising nucleotide sequences encoding a VH, a VL, or both a VH and a VL of the antibody of claim 87 .

150. The polynucleotide of claim 149 , wherein the polynucleotide is operably linked to a promoter.

151. A vector comprising the polynucleotide of claim 149 .

152. A cell comprising the polynucleotide of claim 149 .

153. A cell comprising the vector of claim 149 .

154. A cell producing the antibody or antigen-binding fragment of claim 87 .

155. A kit comprising the antibody or antigen-binding fragment of claim 87 .

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BENNETT, BRYDON; CHAMBERLAIN, PHILIP PAUL; HARIHARAN, KANDASAMY; JACKSON, PILGRIM; KHATTRI, ROLI; LEUNG, MONICA; MORRISON, LISA; SUN, JEONGHOON; TORRES, SANAA; CHAN, HENRY H.
To: CELGENE CORPORATION
Reel/Frame 040760/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: KEHRY, MARILYN
To: ANAPTYSBIO, INC.
Reel/Frame 040760/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: ANAPTYSBIO, INC.
To: CELGENE CORPORATION
Reel/Frame 040760/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2016
From: BENNETT, BRYDON; CHAMBERLAIN, PHILIP PAUL; HARIHARAN, KANDASAMY; JACKSON, PILGRIM; KHATTRI, ROLI; LEUNG, MONICA; MORRISON, LISA; SUN, JEONGHOON; TORRES, SANAA; CHAN, HENRY H.
To: CELGENE CORPORATION
Reel/Frame 039885/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2016
From: KEHRY, MARILYN
To: ANAPTYSBIO, INC.
Reel/Frame 039885/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2016
From: ANAPTYSBIO, INC.
To: CELGENE CORPORATION
Reel/Frame 039885/0085 →
Continuity (2)
Provisional Application 62234535 · Sep 29, 2015
Related Publication 20170088618A1 · Mar 30, 2017